Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)

Add to My Stocks
$37.83 $1.1 (2.99%) SRPT stock closing price Jan 13, 2017 (Closing)
Watch Robo Advisor Video of SRPT Stock Analysis
Sarepta Therapeutics
Updated on : Jan 13, 2017
previous close
SRPT 37.8 (0%)
S&P 500 2274.6 (0%)
Closing Price On: Jan 13, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-52%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
21.1M
Debt/Equity Ratio:
 0.05
Compared to the industry
Cash Flow
Operating cash flow:
-$164.6M
Net Income:
-$56.7M
PROS      CONS
Low Debt Burden
Recent Growth
Long Term Growth
Net Margins
ROE
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
-113.1%
Double Tap To Exit Full Screen
0:00
/

Sarepta Therapeutics Analysis Video

126 5 2

View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.

Sarepta Therapeutics Inc Stock Rating (1.3/5)

Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy SRPT stock?

  • With a debt/equity ratio of  0.05, Sarepta Therapeutics is comparatively less leveraged than its peers in the Medical sector.

Should you sell SRPT stock?

  • Sarepta Therapeutics revenue saw a decline of -999% YoY in 2016 Q3.
  • The company saw an average annual sales decline of in sales over the last 5 years.
  • Over the last 12 months, Sarepta Therapeutics had an average Net loss of -19479.2%.
  • A negative ROE of -113.1% indicates that the company is not able to generate profits with the money shareholders have invested.

Comments on this video and Sarepta Therapeutics stock